A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.

The move comes after a death in the Alpha-3 cema-cel study.

The company gets another odronextamab knockback, while a key fianlimab readout is postponed.

The first data are dribbled out, but cross-trial comparisons look uninspiring.

Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.